Brind.
  1. Ascentage Pharma Group International is focusing on therapies in mainland China, with FDA clearance for lisaftoclax highlighting recent advancements.

Company management of Ascentage Pharma Group International participated in a conference held in Suzhou.

2 reports, 1 independent Updated Jul 23
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Company management of Ascentage Pharma Group International participated in a conference held in Suzhou.

Who's involved

What this event is mainly about
Suzhou

Keep exploring

Part of

Ascentage Pharma Group International is focusing on therapies in mainland China, with FDA clearance for lisaftoclax highlighting recent advancements. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAscentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 ROCKVILLE, Md. and SUZHOU, China, July 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; H
  • GlobeNewswireAscentage Pharma Announces Proposed Top-Up Placement ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascenta